Side by side

Compound comparison

Rapamycin

FDA-approved · Grade B

Goals

longevity, immune

Evidence

4 RCT / 6 animal / 4 in vitro

Routes

oral

WADA

FDA

Approved

Cancer caution

caution

Typical dose

—

Half-life

Rapamycin has a longer half-life (~62 hours) and typically lower bioavailability from oral dosing than everolimus

Primary mechanism

FKBP12 binding

OTC · Grade C

Goals

longevity

Evidence

1 RCT / 5 animal / 4 in vitro

Routes

oral

WADA

FDA

Not approved

Cancer caution

none

Typical dose

—

Half-life

(4) Rapidly cleared from plasma with a short half-life (~1-2 hours in rats)

Primary mechanism

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

Research chemical · Grade C

Goals

cognition, longevity, mitochondria

Evidence

1 RCT / 5 animal / 4 in vitro

Routes

oral

WADA

FDA

Not approved

Cancer caution

caution

Typical dose

—

Half-life

—

Primary mechanism

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.

FDA-approved · Grade C

Goals

longevity, weight-loss, mitochondria, gut

Evidence

10 RCT / 4 animal / 3 in vitro

Routes

oral

WADA

FDA

Approved

Cancer caution

none

Typical dose

—

Half-life

—

Primary mechanism

Mechanism diagram showing the compound's primary signaling pathway and downstream effects.